Slingshot Therapeutics has launched ALTx Therapeutics with funding worth £12.55 million ($17.04 million) to develop novel treatments for cancer.  ALTx Therapeutics launched into the Slingshot accelerator with backing from Syncona, the Francis Crick Institute and Cancer Research Horizons.  Spinning out of the Crick, ALTx is focused on developing therapeutics targeting vulnerabilities in cancers that rely on the Alternative Lengthening of Telomeres […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!